The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
ConroyT., DesseigneM., YchouM.Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. J Clin Oncol.2010; 28(15 suppl): 4010.
2.
BreysacherG., KaatzO., LemarignierC.Safety and clinical efficacy of FOLFIRINOX in metastatic pancreas cancer (MPC) after first-line chemotherapy. Poster session presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 22-24, 2010; Orlando, Florida. Abstract 269.
3.
AssafE., Verlinde-CarvalhoM., DelbaldoC.5-FU/leucovorin (5FU/LV) combined with irinotecan (CPT-11) and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol.2010; 28(15 suppl): e14584.
4.
YchouM., DesseigneF., GuimbaudR.Randomized phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O] vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD 11 trial. J Clin Oncol.2007; 25(18 suppl): 4516.
5.
ConroyT., PaillotB., FrancoisE.Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer – a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol.2005; 23(6): 1228–1236.
6.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology – Pancreatic adenocarcinoma. V.2.2011). NCCN Web site. NCCN.org Accessed April 23, 2011.
7.
YchouM., ViretF., KramarA.Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol.2008; 62(2): 195–201.
8.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology – Antiemesis. V.3.2011. NCCN Web site. NCCN.org. Accessed April 23, 2011.
9.
Multinational Association of Supportive Care in Cancer antiemetic guidelines.www.mascc.org Multinational Association of Supportive Care in Cancer Web site. Published March 2008. Accessed June 5, 2010.
10.
GelingO., EichlerH.G.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
11.
GammonD., BhargavaP., McCormickM.J.Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol. Oncologist.2004; 9(5): 546–549.
12.
SyrigouE.I., KarapanagiotouE.M., AlamaraC.V., BouraP.G., SaifM.W., SyrigosK.N.Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol. Clin Colorectal Cancer.2009; 8(2): 106–109.
13.
KimB.H., BradleyT., TaiJ., BudmanD.R.Hypersensitivity to oxaliplatin an investigation of incidence and risk factors and literature review. Oncology.2009; 76(4): 231–238.
14.
PolyzosA., TsavarisN., GogasH.Clinical features of hypersensitivity reactions to oxaliplatin 10-year experience. Oncology.2009; 76(1): 36–41.
15.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology – Myeloid growth factors. - V.1.2011. NCCN Web site. NCCN.org. Accessed April 23, 2011.
16.
MarounJ.A., AnthonyL.B., BlaisN.Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on chemotherapy-induced diarrhea. Curr Oncol.2007; 14(1): 13–20.
17.
BensonA.B., AjaniJ.A., CatalanoR.B.Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol.2004; 22(14): 2918–2926.
18.
Product information: Eloxatin.Bridgewater, NJ: sanofi-aventis U.S. LLC; 2009.
19.
GamelinE., GamelinL., BossiL.Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol.2002; 29(5 suppl. 15): 21–33.
KurnialiP.C., LuoL.G., WeitbergA.B.Role of calcium/magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients. Oncology.2010; 24(3): 289–292.
22.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21(1): 33–64.
TakimotoC.H., GrahamM.A., LockwoodG.Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res.2007; 13(16): 4832–4839.
25.
FloydJ., MirzaI., SachsB., PerryM.C.Hepatotoxicity of chemotherapy. Semin Oncol.2006; 33: 50–67.
26.
SynoldT.W., TakimotoC.H., DoroshowJ.H.Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res.2007; 13(12): 3660–3666.
27.
SoubraneO., BrouquetA., ZalinskiS.Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases. Ann Surg.2010; 251(3): 454–460.
